JP7324710B2 - 肺癌の処置のための抗ｐｄ－１抗体 - Google Patents

肺癌の処置のための抗ｐｄ－１抗体 Download PDF

Info

Publication number
JP7324710B2
JP7324710B2 JP2019545324A JP2019545324A JP7324710B2 JP 7324710 B2 JP7324710 B2 JP 7324710B2 JP 2019545324 A JP2019545324 A JP 2019545324A JP 2019545324 A JP2019545324 A JP 2019545324A JP 7324710 B2 JP7324710 B2 JP 7324710B2
Authority
JP
Japan
Prior art keywords
antibody
tumor
patient
treatment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019545324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508317A (ja
JP2020508317A5 (enExample
Inventor
ペトラ・リーチェル
イザレル・ロウィ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020508317A publication Critical patent/JP2020508317A/ja
Publication of JP2020508317A5 publication Critical patent/JP2020508317A5/ja
Priority to JP2022037781A priority Critical patent/JP7384949B2/ja
Application granted granted Critical
Publication of JP7324710B2 publication Critical patent/JP7324710B2/ja
Priority to JP2023190525A priority patent/JP7656012B2/ja
Priority to JP2025044340A priority patent/JP2025098103A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019545324A 2017-02-21 2018-02-20 肺癌の処置のための抗ｐｄ－１抗体 Active JP7324710B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022037781A JP7384949B2 (ja) 2017-02-21 2022-03-11 肺癌の処置のための抗ｐｄ－１抗体
JP2023190525A JP7656012B2 (ja) 2017-02-21 2023-11-08 肺癌の処置のための抗ｐｄ－１抗体
JP2025044340A JP2025098103A (ja) 2017-02-21 2025-03-19 肺癌の処置のための抗ｐｄ－１抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762461672P 2017-02-21 2017-02-21
US62/461,672 2017-02-21
US201762595190P 2017-12-06 2017-12-06
US62/595,190 2017-12-06
PCT/US2018/018747 WO2018156494A1 (en) 2017-02-21 2018-02-20 Anti-pd-1 antibodies for treatment of lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022037781A Division JP7384949B2 (ja) 2017-02-21 2022-03-11 肺癌の処置のための抗ｐｄ－１抗体

Publications (3)

Publication Number Publication Date
JP2020508317A JP2020508317A (ja) 2020-03-19
JP2020508317A5 JP2020508317A5 (enExample) 2021-07-26
JP7324710B2 true JP7324710B2 (ja) 2023-08-10

Family

ID=61628468

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019545324A Active JP7324710B2 (ja) 2017-02-21 2018-02-20 肺癌の処置のための抗ｐｄ－１抗体
JP2022037781A Active JP7384949B2 (ja) 2017-02-21 2022-03-11 肺癌の処置のための抗ｐｄ－１抗体
JP2023190525A Active JP7656012B2 (ja) 2017-02-21 2023-11-08 肺癌の処置のための抗ｐｄ－１抗体
JP2025044340A Pending JP2025098103A (ja) 2017-02-21 2025-03-19 肺癌の処置のための抗ｐｄ－１抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022037781A Active JP7384949B2 (ja) 2017-02-21 2022-03-11 肺癌の処置のための抗ｐｄ－１抗体
JP2023190525A Active JP7656012B2 (ja) 2017-02-21 2023-11-08 肺癌の処置のための抗ｐｄ－１抗体
JP2025044340A Pending JP2025098103A (ja) 2017-02-21 2025-03-19 肺癌の処置のための抗ｐｄ－１抗体

Country Status (12)

Country Link
US (3) US11292842B2 (enExample)
EP (2) EP3585812B1 (enExample)
JP (4) JP7324710B2 (enExample)
KR (2) KR102628557B1 (enExample)
CN (2) CN117442719A (enExample)
AU (2) AU2018225102B2 (enExample)
CA (1) CA3054289A1 (enExample)
IL (3) IL268479B2 (enExample)
MA (1) MA47604A (enExample)
MX (2) MX2019009772A (enExample)
WO (1) WO2018156494A1 (enExample)
ZA (2) ZA201905051B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160053301A1 (en) 2014-08-22 2016-02-25 Clearfork Bioscience, Inc. Methods for quantitative genetic analysis of cell free dna
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
KR102505122B1 (ko) 2016-08-25 2023-03-08 레졸루션 바이오사이언스, 인크. Dna 샘플 중 게놈 카피 변화의 검출을 위한 방법
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
CN117442719A (zh) * 2017-02-21 2024-01-26 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
WO2019081750A1 (en) * 2017-10-27 2019-05-02 Statens Serum Institut VACCINE AGAINST POLYGENIC INFLUENZA
US12668635B1 (en) 2017-11-21 2026-06-30 Arcus Biosciences, Inc. Methods of treating solid tumors using an anti-PD-1 antibody or a fragment thereof
CN113544144A (zh) 2018-09-19 2021-10-22 高山免疫科学股份有限公司 变体cd80融合蛋白和相关构建体的方法和用途
DK3880186T3 (da) 2018-11-14 2024-06-03 Regeneron Pharma Intralæsional administration af pd-1-hæmmere til behandling af hudcancer
SG11202107395VA (en) * 2019-01-21 2021-08-30 Sanofi Sa Therapeutic rna for advanced stage solid tumor cancers
SG11202108089SA (en) * 2019-02-28 2021-08-30 Regeneron Pharma Administration of pd-1 inhibitors for treating skin cancer
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
TW202138006A (zh) * 2019-12-13 2021-10-16 韓商三星Ｂｉｏｅｐｉｓ股份有限公司 穩定之抗-pd1抗體醫藥調配物
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
FI4117667T3 (fi) * 2020-03-13 2025-02-10 Univ Texas Syöpien jaksottainen hoito käyttäen 6-tio-dg- ja tarkistuspisteen inhibiittoreita
CN117043193A (zh) * 2021-02-11 2023-11-10 瑞泽恩制药公司 通过施用新辅助pd-1抑制剂治疗癌症的方法
US20250270321A1 (en) * 2021-02-23 2025-08-28 Regeneron Pharmaceuticals, Inc. Methods of treating lung cancer by administering a pd-1 inhibitor
CN119255817A (zh) * 2022-03-28 2025-01-03 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
EP4598960A1 (en) * 2022-10-05 2025-08-13 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)
WO2025030110A1 (en) * 2023-08-02 2025-02-06 Sensei Biotherapeutics, Inc. Cancer therapies targeting vista as monotherapy or in combination with anti-pd1 antibody to treat cancer
JP2026516516A (ja) 2024-01-24 2026-05-25 エルジー エナジー ソリューション リミテッド 電極タブ溶接装置及び電極タブ溶接方法
WO2025207705A1 (en) 2024-03-26 2025-10-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
TW202606706A (zh) 2024-04-05 2026-02-16 美商安進公司 使用ｍｔａ協作的ｐｒｍｔ５抑制劑的胃腸癌治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505125A (ja) 2014-01-23 2017-02-16 リジェネロン・ファーマシューティカルズ・インコーポレ Ｐｄ−１に対するヒト抗体

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
CA2698419C (en) 2007-09-07 2019-11-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
WO2014018498A1 (en) 2012-07-23 2014-01-30 Meadwestvaco Calmar, Inc. Aerosol actuators, devices, and methods of making and using the same
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2015030929A1 (en) 2013-08-30 2015-03-05 Ebay, Inc. Keyword bid optimization for text ads
US10241115B2 (en) 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
WO2015196051A1 (en) 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
CA2968680A1 (en) * 2014-12-02 2016-06-09 Celgene Corporation Combination therapies
EP3254110B1 (en) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
DK3294770T4 (da) * 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
EP4086285A1 (en) 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
CN117442719A (zh) * 2017-02-21 2024-01-26 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN120344265A (zh) * 2022-10-03 2025-07-18 里珍纳龙药品有限公司 单独使用双特异性EGFR x CD28抗体或其与抗PD-1抗体组合使用治疗癌症的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505125A (ja) 2014-01-23 2017-02-16 リジェネロン・ファーマシューティカルズ・インコーポレ Ｐｄ−１に対するヒト抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ａｎｎａｌｓ ｏｆ Ｏｎｃｏｌｏｇｙ， ２０１４年， Ｖｏｌ．２５， Ｓｕｐｐｌ．３， ｉｉｉ２７－３９

Also Published As

Publication number Publication date
IL308805A (en) 2024-01-01
WO2018156494A1 (en) 2018-08-30
IL308805B1 (en) 2025-08-01
US11926668B2 (en) 2024-03-12
MX2019009772A (es) 2019-12-02
JP2025098103A (ja) 2025-07-01
JP2022078265A (ja) 2022-05-24
ZA201905051B (en) 2025-06-25
IL268479A (en) 2019-09-26
US20200010550A1 (en) 2020-01-09
AU2018225102B2 (en) 2024-11-14
MA47604A (fr) 2020-01-01
US11292842B2 (en) 2022-04-05
US20240209090A1 (en) 2024-06-27
EP4772195A2 (en) 2026-07-08
MX2024000780A (es) 2024-02-06
IL321717A (en) 2025-08-01
IL268479B2 (en) 2024-06-01
JP2020508317A (ja) 2020-03-19
CN110536905A (zh) 2019-12-03
EP3585812A1 (en) 2020-01-01
ZA202212891B (en) 2026-03-25
KR20240011262A (ko) 2024-01-25
JP7656012B2 (ja) 2025-04-02
KR20190120792A (ko) 2019-10-24
AU2018225102A1 (en) 2019-09-05
EP3585812B1 (en) 2026-07-01
RU2019129506A3 (enExample) 2021-07-02
CN117442719A (zh) 2024-01-26
KR102628557B1 (ko) 2024-01-29
JP2024016192A (ja) 2024-02-06
US20220281979A1 (en) 2022-09-08
CN110536905B (zh) 2023-10-27
IL268479B1 (en) 2024-02-01
CA3054289A1 (en) 2018-08-30
AU2025201018A1 (en) 2025-03-06
JP7384949B2 (ja) 2023-11-21
RU2019129506A (ru) 2021-03-23
IL308805B2 (en) 2025-12-01

Similar Documents

Publication Publication Date Title
JP7384949B2 (ja) 肺癌の処置のための抗ｐｄ－１抗体
JP7624033B2 (ja) Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
EA045900B1 (ru) Комбинация антител против pd-1 и облучения для лечения злокачественной опухоли

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210519

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211207

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230731

R150 Certificate of patent or registration of utility model

Ref document number: 7324710

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153